Remember meForgot password?
    Log in with Twitter
Press Release

Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto

PR Newswire

QUÉBEC CITY, June 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Brian H. Kushner, MD, of the Memorial Sloan-Kettering Cancer Center in New York, will be making a poster presentation on Phase 1 results for perifosine in neuroblastoma, at the Advances in Neuroblastoma Research Conference which will be held June 18-21, 2012, at the Fairmount Royal York Hotel in Toronto.

Poster #POC27:  "Targeting PI3K/Akt Pathway: Perifosine Monotherapy for Resistant Neuroblastoma in a Phase 1/1B Study", B. Kushner, N-K.V. Cheung, S. Modak, O. Becher, E.M. Basu, S.S. Roberts, K. Kramer, I.J. Dunkel.
Date and time:   Wed., June 20, 2012, 12:30 pm - 2:30 pm + 5:30 pm - 6:30 pm (Eastern)
Venue:    Royal Canadian Ballroom, Fairmount Royal York Hotel, Toronto

About Perifosine

Perifosine is a novel, oral PI3K/Akt inhibitor compound. It is currently in a Phase 3 trial in multiple myeloma for which it has been granted orphan drug and Fast Track designations by the Food and Drug Administration (FDA), as well as positive Scientific Advice and orphan medicinal product designation from the European Medicines Agency. It has also been granted orphan drug designation by the FDA for neuroblastoma. Furthermore, perifosine is in earlier-stage development for other cancer indications.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit